Online inquiry

IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ422MR)

This product GTTS-WQ422MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets AMHR2 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001164690.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 269
UniProt ID Q16671
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ422MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8906MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ11710MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ2438MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ13888MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ11413MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ5577MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ5154MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAN34D3-65
GTTS-WQ8188MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HL161
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW